echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > China Resources Shuanghe acquired Xiangzhong Pharmaceuticals to take an 80% share of the region

    China Resources Shuanghe acquired Xiangzhong Pharmaceuticals to take an 80% share of the region

    • Last Update: 2021-02-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    China Resources bought another pharmaceutical company!

    China Resources Shuanghe Holdings Xiangzhong Pharmaceuticals
    On August 11, China Resources Shuanghe issued the Announcement on the Acquisition of a 40.65% Stake in Hunan Xiangzhong Pharmaceutical Co., Ltd., announcing that Xiangzhong Pharmaceuticals will be included as its controlling subsidiary.
    after acquiring a 45% stake in Hunan Xiangzhong Pharmaceutical Co., Ltd. in May 2018, China Resources Shuanghe has publicly delisted a 40.65 percent stake in Xiangzhong Pharmaceutical Co., Ltd., according to the
    announcement. Since then, it has held 85.65 per cent of Xiang zhongpharma and 14.35 per cent of the other 22 natural person shareholders.

    spent a total of 227 million yuan
    holding Xiang, China Resources Shuanghe took less than three months.
    April 23, 2018, Chongqing Corey Pharmaceuticals was listed on the Chongqing Stock Exchange to transfer its 45% stake in Xiang zhong pharmaceutical company with a listing floor price of RMB143 million.
    May 24, 2018, China Resources Shuanghe obtained a 45% stake in Xianghua Pharmaceuticals through the Chongqing Stock Exchange for RMB143 million. The acquisition of a 40.65 per cent stake, China Resources Shuanghe said, was worth $129m. Won Xiang zhong pharmaceutical, twice a total cost of 227 million.
    Take 80% of the regional market share
    public information shows that Hunan Xiang zhong Pharmaceutical Co., Ltd., founded on March 5, 1998, is the national anti-epileptic drug production base, the main products are sodium valproate, valpropylamine, magnesium acrylic, magnesium valproate slow release tablets.
    of which valproic acid products occupy 80% of the market share of similar products in the country. This is exactly what attracts China Resources twin cranes.
    China Resources Shuanghe previously revealed that the stake in Xiang zhong is to build a spiritual, neurosurgery drug product group, accelerate the spiritual / neurological field of new products landing, enhance the investment agent customer resources and marketing strength, especially rich psychiatric hospital sales network;
    comes after another acquisition by China Resources Shuanghe.
    June 4, China Resources Shuanghe announced that it will use its own funds to acquire a 40% stake in China Resources Shuanghe Limin Pharmaceuticals (Jinan) Co., Ltd. for 847.66 million yuan. Upon completion of this acquisition, it will hold a 100% stake in China Resources Shuanghe Limin Pharmaceuticals (Jinan) Co., Ltd. (Seber Blue)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.